Search results
Results From The WOW.Com Content Network
Lercanidipine (trade name Zanidip, among others) is an antihypertensive (blood pressure lowering) drug. It belongs to the dihydropyridine class of calcium channel blockers , which work by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body.
A study in 2000 found that long-term benzodiazepine therapy does not result in brain abnormalities. [75] Withdrawal from high-dose use of nitrazepam anecdotally was alleged in 2001 to have caused severe shock of the whole brain with diffuse slow activity on EEG in one patient after 25 years of use. After withdrawal, abnormalities in hypofrontal ...
A fact from Lercanidipine appeared on Wikipedia's Main Page in the Did you know column on 11 August 2016 (check views). The text of the entry was as follows: Did you know... that grapefruit juice may amplify the antihypertensive effect of lercanidipine? A record of the entry may be seen at Wikipedia:Recent additions/2016/August.
Calcium channel blocker toxicity is the taking of too much of the medications known as calcium channel blockers (CCBs), either by accident or on purpose. [3] This often causes a slow heart rate and low blood pressure. [1]
Each year, RSV infections cause about 177,000 hospitalizations and 14,000 deaths in adults aged 65 and older, per CDC data. It also leads to about 58,000 hospitalizations and 500 deaths in ...
A 2005 meta-analysis showed modest benefits (33% decrease in attack severity, 2.8-5 reduction in absolute number of attacks per week); it does conclude that most included studies used low doses of nifedipine. [17] Topical nifedipine has been shown to be as effective as topical nitrates for anal fissures. [18]
A case study of two brothers with the condition, two years of treatment with hydrochlorothiazide reduced the incidence of kidney stones and improved kidney function. [22] The thiazide-like diuretic chlortalidone reduced urine calcium oxalate in seven of the eight males with inactivated CLCN5 gene that participated in the study. [ 23 ]
In the last two years of the study, all participants were switched to placebo. By the end of the study, candesartan had significantly reduced the risk of hypertension, by more than 15%. Serious adverse effects were more common among participants receiving placebo than in those given candesartan.